Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.

Abstract

We analyzed 27 CML patients treated with imatinib (IM) who developed a BCR-ABLT315I mutation. These patients had poor prognostic features: High or intermediate Sokal index (82%), and lack of CCyR under IM (59%). At T315I discovery, patients were in advanced phase (59%), with clonal evolution (84%). Median time since diagnosis was 39 months, and progression occurred 13 months after IM initiation, regardless of disease phase. Overall survival since IM initiation was 42.5 months for chronic, and 17.5 months for advanced phases, and all patients progressed. This mutation seems related to or (partially?) responsible for progression and poor survival.

• Authors: Franck E Nicolini, Sandrine Hayette, Selim Corm, Emmanuel Bachy, Dominique Bories, Michel Tulliez, François Guilhot, Laurence Legros, Frédéric Maloisel, Jean-Jacques Kiladjian, François-Xavier Mahon, Quoc-Hung Lê, Mauricette Michallet, Catherine Roche-Lestienne, Claude Preudhomme
• Journal: Haematologica (Haematologica) Vol. 92 Issue 9 Pg. 1238-41 (Sep 2007) ISSN: 1592-8721 [Electronic] Italy
• PMID: 17768119 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Benzamides
• Piperazines
• Pyrimidines
• Imatinib Mesylate
• Protein-Tyrosine Kinases
• Fusion Proteins, bcr-abl

Topics

• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Benzamides
• Drug Resistance, Neoplasm (genetics)
• Female
• Fusion Proteins, bcr-abl (genetics)
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Male
• Middle Aged
• Mutation (genetics)
• Piperazines (therapeutic use)
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Pyrimidines (therapeutic use)
• Retrospective Studies